Efficacy and safety of hydroxychloroquine for Japanese patients with rheumatoid arthritis

Kaneko Yuko0 个研究点目标入组 60 人开始时间: 2018年12月7日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

We investigated the efficacy and safety of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA). HCQ was administered to active RA despite conventional synthetic disease-modifying antirheumatic drugs for 24 weeks, in addition to prior treatment. The primary endpoint, the proportion of ACR20 achievements at week 24, was significantly higher in HCQ group compared to that of a propensity score matched control group. Neither hydroxychloroquine retinopathy nor any new safety signal was observed.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•Rheumatoid arthritis patients with active disease (DAS28 greater than or equal to 2.6) over 18 years old

排除标准

•Contraindication to HCQ, e.g. history of retinopathy and hypersensitivity to 4-aminoquinoline

研究者

发起方

Kaneko Yuko

相似试验

已完成

2 期

Efficacy and safety of hydroxychloroquine for Japanese patients with rheumatoid arthritisrheumatoid arthritis

JPRN-UMIN000023989Division of Rheumatology, Keio University School of Medicine60

已完成

3 期

Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19Pneumonia, PneumocystisCoronavirusCOVID-19

NCT04261517Shanghai Public Health Clinical Center30

撤回

3 期

Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health ProfessionalsCOVID19Sars-CoV2HydroxychloroquineProphylaxisHealthcare Worker

NCT04349228Abderrahmane Mami Hospital

已完成

2 期

Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic CancerPancreatic Cancer

NCT01273805Dana-Farber Cancer Institute20

已完成

不适用

Monitoring and Preventing Hydroxychloroquine, Plaquenil, Toxicity.Hydroxychloroquine Toxicity

NCT03316092Dr. S.S. Michel Clinic1,000